Genadyne Biotechnologies launched by Shahzad Pirzada and the manufacturer of negative pressure wound therapy systems and a host of other therapeutic products has been awarded a Group Purchasing Order (GPO) by The MED Group, a subsidiary of Managed Health Care Associates, Inc. The MED Group is a Group Purchasing and Business Solutions Organization committed to helping medical equipment providers lower their purchasing costs for home medical equipment, health care, technology and other supplies.
“Genadyne’s successful growth plans have been supported by products, service, and educational platforms while helping reduce healthcare costs,” says the founder and President of Genadyne Biotechnologies, Shahzad Pirzada, throwing light on the common philosophies shared by Genadyne and the MED Group. “The new partnership will help both companies identify newer ways of improving our product offerings and reaching them across a wider audience.”
Genadyne’s unwavering mission is to promote wound healing, decrease wound recurrence, and maintain the dignity, independence, comfort levels and pain control of the wound care patient through their advanced and innovatively designed products. The company has over 14 years of experience in developing technologies associated with respiratory products, primarily in the areas of CPAP, BIPAP and portable oxygen delivering systems.
The founder President, Shahzad Pirzada, holds 11 patents with many others pending approval, for air floatation surfaces, non-powered air surfaces, wireless weight scale systems, and unique blood circulation devices. Pirzada is originally a pilot by profession and is trained in avionics and aeronautical engineering from the College of Aeronautics in New York.
The MED Group also helps its partner members increase patient referral revenue and improve efficiencies in marketing programs, education and training, reimbursement, accreditation, certification, logistics and other operational areas. The group organizes numerous programs and services to create value for their customers. The MED Group is in its 40th year of unwavering and fully focused service and serves more than 365 market leaders spread over 1000 locations.
The contract was negotiated by VP (Operations) of Genadyne, Chien-Ming (Andrew) who is credited with developing the Negative Pressure Wound Therapy Systems. The highly experienced professional has also played a stellar role in developing numerous other wound care products and wireless telemetry software solutions. Andrew holds an M.B.A. in Finance from City University of New York-Baruch College and a B.S. in Electrical Engineering from the State University of Buffalo.
The company driven by the enterprising leadership of Shahzad Pirzada continues on its amazing growth path and has recently expanded their services and products into newer global markets to bring Genadyne’s suite of specialty mattresses, and the XLR8 Advanced Negative Pressure Wound Therapy to help reduce and treat wound occurrence.